10,000 patients to reveal how safe midline catheters really are

NCT ID NCT07677696

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study follows 10,000 adults receiving a midline catheter for intravenous therapy lasting 1 to 4 weeks as part of routine care. Researchers track complications like infection, blockage, or blood clots to see how well these devices perform in everyday hospital settings. The goal is to provide clear evidence on whether midline catheters are a safe and effective choice for short-term IV access.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

midline catheter

What this could lead to

If successful, this study could confirm that midline catheters are a safe and effective option for short-term intravenous therapy, potentially reducing complications from other vascular access devices.

What could go wrong

As an observational study, it cannot prove cause and effect. Results may be influenced by differences in patient care or data collection across hospitals.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASCULAR ACCESS DEVICES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Zibo Central Hospital

    RECRUITING

    Zibo, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••